Palo Alto Investors’s UroGen Pharma URGN Stock Holding History

Palo Alto Investors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$441K	Hold	24,500	–	–	0.07%	49
2025 Q4	$574K	Hold	24,500	–	–	0.08%	45
2025 Q3	$489K	Hold	24,500	–	–	0.09%	41
2025 Q2	$336K	Hold	24,500	–	–	0.07%	43
2025 Q1	$271K	Hold	24,500	–	–	0.05%	40
2024 Q4	$261K	Hold	24,500	–	–	0.04%	39
2024 Q3	$311K	Hold	24,500	–	–	0.04%	44
2024 Q2	$411K	Hold	24,500	–	–	0.05%	39
2024 Q1	$368K	Hold	24,500	–	–	0.04%	38
2023 Q4	$368K	Hold	24,500	–	–	0.03%	34
2023 Q3	$343K	Hold	24,500	–	–	0.03%	29
2023 Q2	$254K	Hold	24,500	–	–	0.02%	30
2023 Q1	$226K	Hold	24,500	–	–	0.02%	30
2022 Q4	$217K	Hold	24,500	–	–	0.02%	28
2022 Q3	$204K	Hold	24,500	–	–	0.02%	32
2022 Q2	$201K	Hold	24,500	–	–	0.02%	31
2022 Q1	$213K	Hold	24,500	–	–	0.02%	35
2021 Q4	$233K	Hold	24,500	–	–	0.01%	37
2021 Q3	$412K	Hold	24,500	–	–	0.02%	37
2021 Q2	$374K	Hold	24,500	–	–	0.02%	40
2021 Q1	$477K	Hold	24,500	–	–	0.03%	39
2020 Q4	$441K	Hold	24,500	–	–	0.02%	37
2020 Q3	$473K	Hold	24,500	–	–	0.03%	39
2020 Q2	$640K	Hold	24,500	–	–	0.04%	36
2020 Q1	$437K	Buy	+24,500	New	+$662K	0.04%	33

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Palo Alto Investors's URGN Position: Q1 2026 in Review

Palo Alto Investors held its UroGen Pharma (URGN) position steady in Q1 2026 at 24,500 shares worth $441K. The position accounts for 0.07% of the portfolio, ranked #49.

Palo Alto Investors first reported a position in URGN in Q1 2020 and has held it in 25 quarters since. The position peaked at $640K in Q2 2020. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

Palo Alto Investors held 24,500 shares of UroGen Pharma worth $441K as of Q1 2026.
Palo Alto Investors left its UroGen Pharma share count unchanged in Q1 2026.
UroGen Pharma made up 0.07% of Palo Alto Investors's portfolio in Q1 2026, its #49 holding.
Palo Alto Investors first reported a position in UroGen Pharma in Q1 2020 and has held it in 25 quarters since.
Palo Alto Investors's UroGen Pharma position peaked at $640K in Q2 2020.
173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.